ASH 2022: Multiple myeloma roundup
ASH 2022: Multiple myeloma roundup
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML
Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates
Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Maximising cancer treatment and research through omics, data sharing, and open science
Epidemiology, detection, and management of NAFLD: a Latin American perspective
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma
What is required to advance data ethics, data sharing, and Open Science across LMICs
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer